EDGAR Filing Documents for 0000950170-24-042789

Form 8-K - Current report:

SEC Accession No. 0000950170-24-042789

Filing Date

2024-04-09

Accepted

2024-04-09 07:05:30

Documents

Period of Report

2024-04-08

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	acrv-20240408.htm iXBRL	8-K	69508
2	EX-4.1	acrv-ex4_1.htm	EX-4.1	130683
3	EX-10.1	acrv-ex10_1.htm	EX-10.1	393517
4	EX-10.2	acrv-ex10_2.htm	EX-10.2	162881
5	EX-10.3	acrv-ex10_3.htm	EX-10.3	54179
6	EX-10.4	acrv-ex10_4.htm	EX-10.4	165338
7	EX-99.1	acrv-ex99_1.htm	EX-99.1	17178
8	GRAPHIC	img28311487_0.jpg	GRAPHIC	16059
	Complete submission text file	0000950170-24-042789.txt		1292164

Data Files

Seq	Description	Document	Type	Size
9	XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT	acrv-20240408.xsd	EX-101.SCH	26942
21	EXTRACTED XBRL INSTANCE DOCUMENT	acrv-20240408_htm.xml	XML	5115

Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472

Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979

Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

IRS No.: 825125532 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41551 | Film No.: 24831097
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)